Consequently, further research is required in optimizing adenylate cyclase activator administration, dosage, and selectivity to maximize their benefits while minimizing risks, ultimately improving their therapeutic application for DMD treatment. This evidence concerns the gene ADCY1 and Duchenne muscular dystrophy.